Boston Business Journal: A Potential Inflection Point for Biogen

Jonathan Gertler was interviewed by the Boston Business Journal around Biogen’s strategic direction. In “Timed release: A potential inflection point nears for Biogen,” the Boston Business Journal looked at Biogen’s “ambitious transformation: to become the dominant player in the risky and increasingly competitive field of neuroscience drugs.”The article noted that Biogen “may need to pull the trigger on more transactions in order to fill gaps in its drug pipeline — and hedge against a failed bet on Alzheimer’s.”Dr. Gertler commented that Biogen will have to be creative across the spectrum. The company already is collaborating with researchers to develop gene therapies in which healthy genes are inserted into cells to replace missing or faulty ones. Subscribers can read and share the article at this link.